-
BSM Squibb acquires Karuna for $14 billion to acquire potential "first in class" therapies
Bristol Myers Squibb and Karuna Therapeutics announced a final acquisition agreement, as Bristol Myers Squibb acquires potential first in class therapies from Karuna for $14 billion. According to the ... -
Merck focuses on the development of next-generation cardiac metabolic drugs and competes with oral weight loss therapies
On June 11th, Robert Davis, CEO of pharmaceutical giant Merck, stated at Goldman Sachs Global Healthcare Conference that the company will focus on developing second-generation and third-generation ca ...